Alejandro Arriero Cabañero

Mr. Alejandro Arriero Cabañero

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EGEdna Elisa Garcia
Edna Elisa Garcia
VBVinnitsa Buzoianu-Anguiano
Vinnitsa Buzoianu-Anguiano
RGRaul Silva Garcia
Raul Silva Garcia
FELIPE ESPARZA SALAZARFELIPE ESPARZA SALAZAR
FELIPE ESPARZA SALAZAR
ACAlejandro Arriero Cabañero
Alejandro Arriero Cabañero
Antonio IbarraAntonio Ibarra
Antonio Ibarra
Spinal cord injury is a traumatic lesion that causes a catastrophic condition in patients, resulting in neuronal deficit and loss of motor and sensory function. That loss is caused by secondary injury events following mechanical damage, which results in cell death. One of the most important events is inflammation, which activates molecules like proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α) that provoke a toxic environment, inhibiting axonal growth and exacerbating CNS damage. As there is no effective treatment, one of the developed therapies is neuroprotection of the tissue to preserve healthy tissue. Among the strategies that have been developed are the use of cell therapy, the use of peptides, and molecules or supplements that have been shown to favor an anti-inflammatory environment that helps to preserve tissue and cells at the site of injury, thus favoring axonal growth and improved locomotor function. In this review, we will explain some of these strategies used in different animal models of spinal cord injury, their activity as modulators of the immune system, and the benefits they have shown.

31 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
EGEdna Elisa Garcia
Edna Elisa Garcia
VBVinnitsa Buzoianu-Anguiano
Vinnitsa Buzoianu-Anguiano
RGRaul Silva Garcia
Raul Silva Garcia
FELIPE ESPARZA SALAZARFELIPE ESPARZA SALAZAR
FELIPE ESPARZA SALAZAR
ACAlejandro Arriero Cabañero
Alejandro Arriero Cabañero
Antonio IbarraAntonio Ibarra
Antonio Ibarra
Spinal cord injury is a traumatic injury that causes a catastrophic state in patients due to neuronal deficits, loss of motor and sensory function, and this is due to secondary deleterious events subsequent to mechanical damage that expands the death of neural cells beyond the initial trauma. One of the most important events is inflammation, which activates molecules like pro-inflammatory cytokines (IL-1beta, IFN-gamma, TNF-alpha) that provoke a toxic environment, inhibiting axonal growth and exacerbating CNS damage. As there is no effective treatment, one of the strategies developed is neuroprotection to preserve healthy neural tissue and reduce neuroinflammation. Some of the neuroprotective treatments that have been practiced are the use of cell therapy, the administration of peptides and molecules or supplements that have been shown to favor an anti-inflammatory environment, and help to preserve the cells and tissues surrounding the injured area, favoring axonal growth and improving locomotor function. In this review we will explain some of these strategies used in different animal models of spinal cord injury, their activity as modulators of the immune system and the benefits they have shown.

8 August 2024 in Cells
Verified
Journal Article
Open access
PDF file
ACAlejandro Arriero Cabañero
Alejandro Arriero Cabañero
EGEdna Elisa Garcia
Edna Elisa Garcia
STStephanie M. Sánchez Torres
Stephanie M. Sánchez Torres
SHSergio Aristizabal Hernandez
Sergio Aristizabal Hernandez
CPConchi Garcia- Rama Pacheco
Conchi Garcia- Rama Pacheco
JMJörg Mey
Jörg Mey
Following spinal cord injury (SCI), the regenerative capacity of the central nervous system (CNS) is severely limited by the failure of axonal regeneration. The regeneration of CNS axons has been shown to occur by grafting predegenerated peripheral nerves (PPNs) and to be promoted by the transplantation of neural precursor cells (NPCs). The introduction of a combinatorial treatment of PPNs and NPCs after SCI has to address the additional problem of glial scar formation, which prevents regenerating axons from leaving the implant and making functional connections. Previously, we discovered that the synthetic sulfoglycolipid Tol-51 inhibits astrogliosis. The objective was to evaluate axonal regeneration and locomotor function improvement after SCI in rats treated with a combination of PPN, NPC, and Tol-51. One month after SCI, the scar tissue was removed and replaced with segments of PPN or PPN+Tol-51; PPN+NPC+Tol-51. The transplantation of a PPN segment favors regenerative axonal growth; in combination with Tol-51 and NPC, 30% of the labeled descending corticospinal axons were able to grow through the PPN and penetrate the caudal spinal cord. The animals treated with PPN showed significantly better motor function. Our data demonstrate that PPN implants plus NPC and Tol-51 allow successful axonal regeneration in the CNS.


5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
VBVinnitsa Buzoianu-Anguiano
Vinnitsa Buzoianu-Anguiano
ACAlejandro Arriero Cabañero
Alejandro Arriero Cabañero
AFAlfonso Fernández-Mayoralas
Alfonso Fernández-Mayoralas
CGConcepción García-Rama
Concepción García-Rama
JMJörg Mey
Jörg Mey
Ernesto Doncel-PérezErnesto Doncel-Pérez
Ernesto Doncel-Pérez

Verified
Journal Article
Open access
PDF file
VBVinnitsa Buzoianu-Anguiano
Vinnitsa Buzoianu-Anguiano
ACAlejandro Arriero Cabañero
Alejandro Arriero Cabañero
AFAlfonso Fernández-Mayoralas
Alfonso Fernández-Mayoralas
MTMabel Torres-Llacsa
Mabel Torres-Llacsa
Ernesto Doncel-PérezErnesto Doncel-Pérez
Ernesto Doncel-Pérez
Traumatic spinal cord injury (tSCI) has complex pathophysiological events that begin after the initial trauma. One such event is fibroglial scar formation by fibroblasts and reactive astrocytes. A strong inhibition of axonal growth is caused by the activated astroglial cells as a component of fibroglial scarring through the production of inhibitory molecules, such as chondroitin sulfate proteoglycans or myelin-associated proteins. Here, we used neural precursor cells (aldynoglia) as promoters of axonal growth and a fibrin hydrogel gelled under alkaline conditions to support and guide neuronal cell growth, respectively. We added Tol-51 sulfoglycolipid as a synthetic inhibitor of astrocyte and microglia in order to test its effect on the axonal growth-promoting function of aldynoglia precursor cells. We obtained an increase in GFAP expression corresponding to the expected glial phenotype for aldynoglia cells cultured in alkaline fibrin. In co-cultures of dorsal root ganglia (DRG) and aldynoglia, the axonal growth promotion of DRG neurons by aldynoglia was not affected. We observed that the neural precursor cells first clustered together and then formed niches from which aldynoglia cells grew and connected to groups of adjacent cells. We conclude that the combination of alkaline fibrin with synthetic sulfoglycolipid Tol-51 increased cell adhesion, cell migration, fasciculation, and axonal growth capacity, promoted by aldynoglia cells. There was no negative effect on the behavior of aldynoglia cells after the addition of sulfoglycolipid Tol-51, suggesting that a combination of aldynoglia plus alkaline fibrin and Tol-51 compound could be useful as a therapeutic strategy for tSCI repair.